Objective: To describe a case of likely etoricoxib-induced severe thrombocytopenia. Clinical Presentation and Intervention: A 32-year-old woman was referred to our hospital for disseminated petechial rash after 7 days of therapy with etoricoxib. At admission, the patient's platelet count was 3,000/mm(3). At Naranjo's scale correlation between thrombocytopenia and drug was considered as "probable." With the diagnostic tests performed we did not find other causes of thrombocytopenia. Etoricoxib was discontinued. The patient was treated with intravenous immunoglobulin and corticosteroids with a complete resolution of the thrombocytopenia in a few days. Conclusion: The prevalence of thrombocytopenia induced by etoricoxib should be studied as it may not be very rare. (C) 2019 The Author(s) Published by S. Karger AG, Basel.
Guerino Recinella, A.D.M. (2019). Probable Etoricoxib-Induced Severe Thrombocytopenia: A Case Report. MEDICAL PRINCIPLES AND PRACTICE, 28(4), 387-389 [10.1159/000496975].
Probable Etoricoxib-Induced Severe Thrombocytopenia: A Case Report
Guerino Recinella
;Alessandro De Marchi;Enrico Pirazzoli;Giampaolo Bianchi
2019
Abstract
Objective: To describe a case of likely etoricoxib-induced severe thrombocytopenia. Clinical Presentation and Intervention: A 32-year-old woman was referred to our hospital for disseminated petechial rash after 7 days of therapy with etoricoxib. At admission, the patient's platelet count was 3,000/mm(3). At Naranjo's scale correlation between thrombocytopenia and drug was considered as "probable." With the diagnostic tests performed we did not find other causes of thrombocytopenia. Etoricoxib was discontinued. The patient was treated with intravenous immunoglobulin and corticosteroids with a complete resolution of the thrombocytopenia in a few days. Conclusion: The prevalence of thrombocytopenia induced by etoricoxib should be studied as it may not be very rare. (C) 2019 The Author(s) Published by S. Karger AG, Basel.File | Dimensione | Formato | |
---|---|---|---|
case report trombocitopenia 2019.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione
103.19 kB
Formato
Adobe PDF
|
103.19 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.